- Capital Cube•22 days ago
Click here to see latest analysisCapitalcube gives Repligen Corp. a score of 88.Our analysis is based on comparing Repligen Corp. with the following peers – Novavax, Inc., Neurocrine Biosciences, Inc., BioMarin Pharmaceutical Inc., Charles River Laboratories International, Inc., Thermo Fisher Scientific Inc., Caladrius Biosciences, Inc., Bristol-Myers Squibb Company, Sangamo BioSciences, Inc., Pfizer Inc. and General […] (Read more...) The post Repligen Corp. – Value Analysis (NASDAQ:RGEN) : July 1, 2016 appeared first on CapitalCube.
After hours: 27.500.00 (0.00%) as of 5:01 PM EDT
|Ask||35.00 x 200|
|52wk Range||20.07 - 39.17|
|Day's Range||27.14 - 27.69|
|Avg Vol (3m)||300,420|
As of 4:00 PM EDT. Market closed.